Loading resource…

Microlabs
The presentation provides an in-depth analysis of SGLT2 inhibitors, focusing on their mechanisms of action in glucose reabsorption and their therapeutic effects on patients with T2DM, HF, and CKD. It highlights significant clinical trials that demonstrate the efficacy of these medications in improving patient outcomes. Additionally, the document addresses the accessibility and pricing of Tilyptin, a DPP-4 inhibitor, in various regions of Uganda, emphasizing its role in diabetes management.
No account needed